Streetbeat News

Regulatory

GNPX

Genprex has advanced to the highest dose group in its Acclaim-3 trial for Reqorsa gene therapy, in combination with Tecentriq, after receiving approval from the Safety Review Committee.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:29 pm

CRML

Critical Metals Corp (NASDAQ:CRML) has advanced its Tanbreez Rare Earth Mine project in Greenland by securing an extension for its exclusive exploitation license and completing a diamond drilling program. Rare earth material samples have been sent for testing.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:26 pm

BAYRY

Bayer AG has submitted a marketing authorization application to the European Medicines Agency for its menopause drug elinzanetant, following positive Phase 3 trial results. The drug showed significant reduction in vasomotor symptoms and improved quality of life over 52 weeks.

Portfolio Pulse from Vandana Singh

October 15, 2024 | 1:26 pm

NRSN

NeuroSense Therapeutics Ltd. plans to submit a dossier for early commercialization of its ALS treatment, PrimeC, in Canada by Q2 2025, with a regulatory decision expected by Q1 2026. The company estimates a potential market opportunity of $100M-$150M in annual revenue.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:24 pm

ANVS

Annovis Bio's stock is rising following FDA clearance for Phase 3 Alzheimer's studies and alignment of Buntanetap NDAs.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:24 pm

GOOG

GOOGL

OKLO

Oklo Inc (NYSE:OKLO) shares are rising due to momentum from a Google nuclear deal and the U.S. Department of Energy's approval of Oklo's Aurora fuel fabrication facility design report. This positions Oklo for future advancements in nuclear energy.

Portfolio Pulse from Adam Eckert

October 15, 2024 | 1:16 pm

LTRN

Lantern Pharma shares rose after the FDA granted fast-track designation to LP-184 for Glioblastoma treatment.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:14 pm

LTRN

Lantern Pharma's drug candidate LP-184 has received FDA Fast-Track designation for the treatment of glioblastoma, a type of brain cancer. This designation is expected to expedite the development and review process of LP-184, potentially bringing it to market faster.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:08 pm

ALGS

Aligos Therapeutics has announced that abstracts on incremental data from their ALG-000184 in chronic hepatitis B (CHB) subjects and a late-breaker oral presentation of data from the Phase 2a HERALD study of ALG-055009 in metabolic-associated steatohepatitis (MASH) subjects have been accepted at the Liver Meeting 2024.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:08 pm

SEEL

Seelos Therapeutics has received a delisting notice from Nasdaq and will transfer its listing to the Over-the-Counter market.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 1:03 pm